SP1 and pancreatic neoplasm: Minnelide, a drug that has successfully completed Phase 1 trial and is awaiting Phase 2 trial has shown remarkable effect in downregulating a number of key pancreatic cancer pathways like Sp1 and NF-kB mediated signaling.